Signals, Powered By EquityPandit
Zydus Cadila has signed an agreement with Council of Scientific and Industrial Research (CSIR) – Institute of Microbial Technology (IMTECH), to identify new drug candidates for treatment of drug resistant infections.
In a BSE filing the company stated that, the collaborative research agreement will have scientists from both organisations working together on microbiology and genomics to identify new lead candidate as novel anti-tuberculosis compound.
Further, scientists at IMTECH will use their expertise and scientific knowledge in microbiology, while Zydus Cadila will provide expertise in medicinal chemistry and pharmaceutical drug development to develop new drug combinations, against drug-resistant pathogens which causes severe diseases in India and across the world.
